Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708793 | 0.94 | PDE11A (0.41) | PDE5A | |
| SCHEMBL6710430 | 0.92 | PDE11A (0.34) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL6709069 | 0.91 | P2RX7 (0.33) | PDE5AHDAC6HDAC1PDE3A | |
| Bicarbonate SCHEMBL7002335 | 0.91 | PDE5A (0.42) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL6771429 | 0.88 | PDE5A (0.46) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL6712239 | 0.88 | PDE11A (0.41) | PDE5A | |
| SCHEMBL6708899 | 0.87 | PDE5A (0.44) | PDE5AHDAC6HDAC1PDE3AHDAC2 | |
| SCHEMBL6706976 | 0.85 | CHRM4 (0.38) | PDE5A | |
| SCHEMBL6763958 | 0.84 | SMN1; SMN2 (0.42) | PDE5A | |
| Bicarbonate SCHEMBL7001344 | 0.84 | PDE5A (0.43) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777419-B1 | EXHIBIT PHOSPHODIESTERASE V INHIBITION AND CAN BE EMPLOYED FOR THE TREATMENT OF DISORDERS OF THE CARDIOVASCULAR SYSTEM OR ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | PDE5A 9/4885HDAC6 2439/4885HDAC1 2539/4885 |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | P2RX3, HRH2, HRH4 | PDE5A 246/4885HDAC6 3458/4885HDAC1 3243/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | PDE5A 7/4885HDAC6 3914/4885HDAC1 3376/4885 |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | DPYD, TYMP, PNPO | PDE5A 851/4885HDAC6 3361/4885HDAC1 3574/4885 |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | PTGIS, PTGIR, PTGER1 | PDE5A 100/4885HDAC6 4182/4885HDAC1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.